Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:13:54 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Q:VTVT - VTV THERAPEUTICS INC - https://www.vtvtherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VTVT - Q0.115.55·46.001.529.02-2.39-7.626.273295431.11  33.035  28.8444.00  14.0017:14:32Feb 0215 min RT 2¢

Recent Trades - Last 10 of 954
Time ETExPriceChangeVolume
17:14:32Q29.00-2.011
16:10:05Q29.02-1.991
16:04:53Q29.02-1.991
16:00:06Q29.02-1.9936
16:00:06Q29.02-1.993
16:00:06Q29.02-1.994
16:00:06Q29.02-1.994
16:00:06Q29.02-1.993
16:00:06Q29.02-1.992
16:00:06Q29.02-1.993

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-02 08:00U:VTVTNews ReleasevTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
2025-12-18 16:05U:VTVTNews ReleasevTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
2025-11-06 16:15U:VTVTNews ReleasevTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-10-09 08:00U:VTVTNews ReleasevTv Therapeutics Announces New Appointments to its Scientific Advisory Board
2025-09-15 08:00U:VTVTNews ReleasevTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting
2025-09-03 16:58U:VTVTNews ReleaseUPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences
2025-09-03 08:00U:VTVTNews ReleasevTv Therapeutics to Participate in Upcoming September Investor Conferences
2025-09-02 08:00U:VTVTNews ReleasevTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund
2025-08-12 16:15U:VTVTNews ReleasevTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
2025-08-11 08:00U:VTVTNews ReleasevTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin
2025-08-07 08:00U:VTVTNews ReleasevTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes
2025-06-11 08:00U:VTVTNews ReleasevTv Therapeutics to Participate in the H.C. Wainwright "HCW@Home" Series
2025-05-19 09:00U:VTVTNews ReleasevTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
2025-05-15 16:01U:VTVTNews ReleasevTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update
2025-05-15 12:00U:VTVTNews ReleasevTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes
2025-03-20 17:36U:VTVTNews ReleasevTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
2025-03-17 08:30U:VTVTNews ReleasevTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes